BioNTech SE (BNTX)

From the record

BioNTech SE's filings since 2019 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

BioNTech SE's 9 filed years say what it did: revenue went from EUR 62 million in fiscal 2017 to EUR 2.9 billion in fiscal 2025, up 61.6% a year; it rose in 4 of 8 years; the deepest fall was 86% from fiscal 2021 to fiscal 2024; net income was positive in 4 of 9 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, BioNTech SE's diluted share count shrank about 1.1% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 27 sales (27 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-10-09 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, BioNTech SE lost about 6 cents for every dollar of shareholders' money, and gross profitability: its products earned about 10 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 13 cents per dollar of assets, and net share issuance: its share count grew 0.5% over the year (the filed statements).

From the record

BioNTech SE's standing among 102 graded names in its industry family: revenue of EUR 2.9 billion in fiscal 2025 is not ranked by size, since the family reports in another currency; a net margin of -39.6% ranks in the top 31%; revenue growth of -45.1% a year over the last 3 filed years ranks in the bottom 13% (its annual reports).

From the record

BioNTech SE's room to grow, from the newest filed statements (fiscal 2025): cash of EUR 7.7 billion against no long-term debt tagged leaves 34.9% of its assets as net cash, top 44% of its family; cash from operations less capital spending is 9.8% of revenue (top 16%); a gross margin of 77.6% (top 37%); research spending of 73.3% of revenue (bottom 37%) (its annual report).

From the record

BioNTech SE's growth drivers, from the filed years to fiscal 2025: revenue grew -45.1% a year over the last three filed years against 61.6% over all 9, slowing (bottom 6% of its family); the newest year grew 4.3% (bottom 41%); research spending grew 11% a year (top 30%); capital spending grew -19% a year (top 41%) (its annual reports). BioNTech SE reported 3 product lines in fiscal 2025: COVID19 Vaccine Revenues at EUR 2.0 billion (70%), Revenues From Out Licensing at EUR 613 million (21%), Other Sales at EUR 262 million (9%); 0 of 2 grew against the year before (its annual report).

From the record

BioNTech SE's newest year against its own record: revenue of EUR 2.9 billion in fiscal 2025 came in 161.5% above the EUR 1.1 billion its prior three years' pace pointed to (top 16% of its family); net income of EUR 1.1 billion against a prior three-year average of EUR 3.2 billion (bottom 11%); a net margin of -39.6% against 18.2% before (bottom 26%) (its annual reports).